GBA1 and Parkinson disease: Ambroxol and LTI-291 (chaperone molecules aimed to increase the level or activity of glucocerebrosidase) and venglustat (a glucosylceramide synthase inhibitor) are now tested in clinical studies for Parkinson’s disease [170].